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Shwachman-Diamond syndrome (SDS), a rare auto-
somal-recessive disorder characterized by exocrine
pancreatic insufficiency and hematopoietic dysfunc-
tion, is caused by mutations in the Shwachman-
Bodian-Diamond syndrome (SBDS) gene. We
created human pluripotent stem cell models of SDS
through knockdown of SBDS in human embryonic
stem cells (hESCs) and generation of induced
pluripotent stem cell (iPSC) lines from two patients
with SDS. SBDS-deficient hESCs and iPSCsmanifest
deficits in exocrine pancreatic and hematopoietic
differentiation in vitro, enhanced apoptosis, and
elevated protease levels in culture supernatants,
which could be reversed by restoring SBDS protein
expression through transgene rescue or by supple-
menting culture media with protease inhibitors.
Protease-mediated autodigestion provides amecha-
nistic link between the pancreatic and hematopoietic
phenotypes in SDS, highlighting the utility of hESCs
and iPSCs in obtaining novel insights into human dis-
ease.
INTRODUCTION
Shwachman-Diamond syndrome (SDS) is a rare pediatric dis-
order characterized by exocrine pancreatic insufficiency,
hematopoietic dysfunction, and predisposition to leukemia. His-
tological examination reveals fatty infiltration of pancreatic acini
with spared ductal architecture (Shimamura, 2006). Neutropenia
is the most frequent hematological abnormality, with limited
progression to aplastic anemia. An increased risk for myelodys-
plasia and acute myelogenous leukemia is the major source of
mortality (Donadieu et al., 2005).SDS is associatedwith inheritedmutations in the Shwachman-
Bodian-Diamond syndrome (SBDS) gene (Boocock et al.,
2003). The majority are nonsense or splice-site mutations that
result in reduced, but not absent, protein expression. No patients
with biallelic null mutations have been identified, and targeted
deletion of murine Sbds results in embryonic lethality, indicating
that some Sbds expression is essential for viability (Zhang et al.,
2006). The two most common mutations are rs113993993,
which affects a donor splice site and leads to premature protein
truncation, and rs120074160, which encodes a premature stop
codon (Boocock et al., 2003; Nakashima et al., 2004).
SBDS is implicated in ribosome biogenesis (Finch et al., 2011).
SBDS protein concentrates in the nucleolus (Austin et al., 2005),
and SBDS deficiency results in delayed ribosomal RNA process-
ing (Ganapathi et al., 2007). Functional 80S ribosomes form
through the assembly of 40S and 60S subunits. Eukaryotic
initiation factor 6 (eIF6) prevents premature intersubunit bridge
formation during pre-60S subunit maturation (Gartmann et al.,
2010); however, eIF6 must be released from the 60S subunit
before the 80S ribosome can form. Sbds is a protein cofactor
that participates in the mechanism by which elongation factor-
like 1 (Efl1) releases eIF6 from the pre-60S subunit (Finch et al.,
2011). Diminished Sbds expression impairs ribosomal subunit
assembly in patients (Burwick et al., 2012).
Human embryonic stem cells (hESCs) and induced pluripotent
stem cells (iPSCs) are valuable tools for studying developmental
dysfunction in genetic disease. Directed differentiation of hESCs
and iPSCs into specific tissues enables detailed study of cell-
fate decisions and provides a scalable in vitro model of early
human development.
In this study, we modeled SDS in hESCs by inducing SBDS
protein deficiency with lentiviral RNAi and derived iPSCs from
the fibroblast cell lines of two patients. SDS hESCs and iPSCs
displayed defective exocrine pancreatic differentiation and
impaired myeloid hematopoietic development. SDS pancreatic
and hematopoietic cultures displayed prominent granular con-
tent, elevated protease activity, and increased cell death. Phar-
macological inhibition of protease activity reversed the cellularCell Stem Cell 12, 727–736, June 6, 2013 ª2013 Elsevier Inc. 727
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Figure 1. Characterization of SDS hESCs and iPSCs
(A) Western blot for SBDS protein expression in lysates of iPSCs generated
from two patients with SDS, hESCs modified by shRNA for SBDS, and a
normal hESC line (BGO1). ‘‘+SBDS’’ indicates transgene-rescued cell lines.
‘‘SBDS’’ indicates control lentiviral infection with empty vector. Loading
control: a-tubulin.
(B) Ribosomal profiles of transgene-rescued (iPSC1+SBDS, top panel) and
SBDS-deficient (iPSC1-SBDS, bottom panel) SDS-iPSC-1. Absolute ratios
with SDs of 80S, 60S, and 40S ribosomal subunits are provided as insets.
See also Figure S1.
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Stem Cell Models of Shwachman-Diamond Syndromephenotypes in vitro, suggesting that granule-processing defects
resulting in pathologic autodigestion and cell death link the
pancreatic and hematopoietic phenotypes.
RESULTS
Generation of Human Pluripotent Stem Cell Lines for
Modeling SDS
We knocked down SBDS in hESCs through lentiviral delivery
of small hairprin RNA (shRNA) and then isolated a stable
knockdown population using fluorescence-activated cell sorting
(FACS) and manual selection of GFP-positive colonies (SBDSi
hESC). We maintained SBDSi hESC as a population to minimize
the phenotypic variation that occurs when selecting individual
clones. In addition, we reprogrammed fibroblast cell lines from
two patients with SDS into iPSCs (SDS-iPSC-1 and SDS-
iPSC-2; Park et al., 2008). We restored normal levels of SBDS
protein expression through transgene rescue by infecting SBDSi
hESC, SDS-iPSC-1, and SDS-iPSC-2 with a lentiviral vector
expressing human SBDS complementary DNA (cDNA) and
selecting for stably corrected populations (hESC+SBDS,
iPSC1+SBDS, and iPSC2+SBDS). We generated control cell
lines with an empty puromycin selectable vector (hESC-SBDS,
iPSC1-SBDS, and iPSC2-SBDS).
Western blotting demonstrated reduced SBDS protein
expression in hESC-SBDS, iPSC1-SBDS, and iPSC2-SBDS
and restoration of protein expression with transgene rescue (Fig-
ure 1A). iPSC1-SBDS showed trace SBDS expression only with
overexposure of the western blot; iPSC2-SBDS displayed
reduced levels of SBDS relative to the control hESC line (Fig-
ure 1A). Fibroblasts used to generate SDS-iPSC-2 were from a
patient who possesses two splice-site mutations and expresses
full-length SBDS messenger RNA (mRNA), although at lower
levels, due to alternative splicing (Austin et al., 2005).
SBDSi hESC, SDS-iPSC-1, and SDS-iPSC-2 kept in culture for
more than 40 passages maintained hallmarks of human pluripo-
tent cells regardless of gene correction. All cell lines showed
>95% positivity for the hESC marker Tra-1-60, formed cystic
trilineage teratomas after injection into immunodeficient mice
(Figure S1A available online), and expressed levels of mRNA
transcripts for the pluripotency markers NANOG, OCT4, SOX2,
and KLF4 comparable to those of control hESC and iPSC lines
(Figure S1B). After 16 days of differentiation in vitro, cells
expressed specific markers reflecting their commitment to
the endoderm (AFP and GATA4), mesoderm (MYOCD and
RUNX1), and ectoderm (NCAM1 and NES; Figure S1C). We
observed no significant differences between SBDS-deficient
and transgene-rescued cell lines, indicating that reduced
SBDS levels do not compromise pluripotency. Although SBDS
deficiency can lead to abnormal mitoses and polyploidy (Austin
et al., 2008), we found that no cell line demonstrated greater
than 5% polyploidy.
Cells from patients and animal models of SDSmanifest SBDS-
dependent reductions in ribosomal assembly, as reflected by
depressed ratios of the 80S and 60S subunits relative to 40S
(Burwick et al., 2012; Wong et al., 2011). We sedimented cell
lysates from iPSC1+SBDS and iPSC1-SBDS through sucrose
gradients, measured ribosomal peaks by UV absorbance, and
determined relative levels of the ribosomal subunits after quanti-728 Cell Stem Cell 12, 727–736, June 6, 2013 ª2013 Elsevier Inc.fication of the area under the curve (Figure 1B). SBDS protein
rescue reversed the depressed 80S:40S and 60S:40S ratios,
consistent with functional correction of the ribosomal subunit
association defects. Thus, our pluripotent stem cell models
reflect defects in ribosomal assembly characteristic of the
disease (Finch et al., 2011).
SBDS Deficiency Compromises Exocrine Pancreatic
Development
Human pluripotent stem cells can be differentiated into pancre-
atic tissue in a stepwise manner that recapitulates cell-fate deci-
sions of pancreatic organogenesis in utero (Cai et al., 2010; Chen
et al., 2009); therefore, we used in vitro directed differentiation to
model pancreatic development in SDS and assessed differenti-
ation at various time points. Differentiation cultures from all cell
lines at day 5 stained positive for FOXA2, a marker of definitive
endoderm, in regions between pluripotent colonies (Figure S2A).
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Figure 2. Impairment of Pancreatic Tissue Development in SDS hESCs and iPSCs
(A) Percentage of cells staining positive for amylase by IF staining at day 25 of pancreatic differentiation in vitro.
(B) IF staining for amylase (orange) and DNA (Hoechst 33342, cyan) in SBDS-deficient (iPSC1-SBDS) and transgene-corrected (iPSC1+SBDS) SDS-iPSC-1 cells
at day 25 of pancreatic differentiation in vitro. Images for SBDSi hESC are comparable (data not shown).
(C) RT-PCR for relative gene expression of exocrine pancreatic markers amylase and carboxypeptidase (CPA1) at day 25 of pancreatic differentiation in vitro. We
normalized results for transgene-rescued cell lines to 100%.
(D) Change in the number of exocrine cells from day 25 to day 35 of in vitro pancreatic differentiation. We normalized results for transgene-corrected cell lines to 1.
(E) Percentage of cells positive for apoptotic marker Annexin V.
Error bars represent SEM; red bars represent transgene-corrected cells; yellow bars represent SBDS-deficient cells. The number of biological replicates was
between 3 and 6 for all data points. *0.01 < p < 0.05; **p < 0.01. See also Figure S2 and Tables S4 and S5.
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Stem Cell Models of Shwachman-Diamond SyndromeWe observed no significant differences in endoderm commit-
ment regardless of gene rescue when evaluating expression of
FOXA2 or SOX17, another endodermal marker (Figure S2B).
We also performed quantitative RT-PCR (qRT-PCR) for FOXA2
and an extraembryonic endodermal marker, AFP, and found
no significant differences in gene expression regardless of
transgene rescue. With the presence of definitive endoderm
established, we then treated cultures with ()-indolactam V, a
compound that directs pancreatic progenitor development
from definitive endoderm (Chen et al., 2009). Pancreatic progen-
itors adopted a streak-like morphology visualized by immuno-
fluorescence (IF) staining for the pancreatic progenitor marker
PDX1. These PDX1+ cells arose from definitive endoderm in
the network of gaps between either original hESC or original
iPSC colonies (Figure S2C). We found similar percentages of
PDX1+ pancreatic progenitors regardless of transgene rescue
(Figure S2D); similarly, qRT-PCR analysis revealed no significant
differences in mRNA expression for PDX1 and the pancreatic
transcriptional regulator hepatocyte nuclear factor 6 (HNF-6).
Therefore, loss of SBDS does not impair definitive-endoderm
formation or generation of pancreatic progenitors from hESCs
and iPSCs.
We then differentiated pancreatic progenitors into mature
pancreatic cell fates. Exocrine acinar cells form the majority of
naturally developed pancreas and pancreatic tissue differenti-
ated in vitro from hESCs (Chen et al., 2009). At day 19 in pancre-
atic differentiation culture, all cell lines displayed greater than
95% amylase positivity irrespective of gene rescue, indicatingthat initial commitment to exocrine cell fate is not SBDS depen-
dent. Culture for an additional 7–10 days produces mature
pancreatic acinar cells. At this later time point (day 25), SBDS-
deficient hESC and SDS-iPSC-1 displayed deficits in amylase
positivity as measured by IF staining (Figures 2A and 2B) and
lower levels of amylase and carboxypeptidase gene expression
as measured by RT-PCR relative to their gene-rescued counter-
parts (Figure 2C). These data suggest that SBDS is essential for
maintaining or preventing loss of exocrine cells at the later
stages of pancreatic differentiation in vitro. We also observed a
continued decrease in exocrine cell number from day 25 to 35
among SBDS-deficient hESCs and SDS-iPSC-1 relative to
gene-rescued cells (Figure 2D), indicating that SBDS-dependent
exocrine cell loss continues over time in culture. SBDS
deficiency accelerates Fas-dependent apoptosis (Rujkijyanont
et al., 2008). Consistent with this, we found elevated levels of
the apoptotic marker Annexin V in SBDS-deficient hESCs and
SDS-iPSC-1 (Figure 2E).
Unlike in hESCs and SDS-iPSC-1, the empty-vector control
for SDS-iPSC-2 (iPSC2-SBDS) did not display a reduction in
exocrine cell number compared to transgene-rescued cells at
day 25 of pancreatic differentiation. We speculated that this
might be due to residual SBDS protein expression in this line.
Thus, we depleted SBDS protein further with lentiviral RNAi
and confirmed the reduction in SBDS expression via western
blot (Figure S2E). In iPSC2-SBDS cells with SBDS RNAi added,
we detected a decrease in amylase-positive cells (Figure 2F), a
decrease in exocrine cells (Figure 2G), and an increase in IFCell Stem Cell 12, 727–736, June 6, 2013 ª2013 Elsevier Inc. 729
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Figure 3. Impairment of Ductal Architecture in SDS hESCs and iPSCs
(A) Photographs of IF staining of transgene-rescued (iPSC1+SBDS) and SBDS-deficient (iPSC1-SBDS) SDS-iPSC-1 for ductal marker DBA (pink) and exocrine
marker amylase (green) at day 25 of in vitro pancreatic differentiation.
(B) Percentage of cells positive for DBA at day 25 of in vitro pancreatic differentiation.
(C) Relative gene expression of pancreatic ductal marker CK19 at day 25 of in vitro pancreatic differentiation as determined by RT-PCR.We normalized results on
cell lines with gene rescue to 100%.
(D) Photomicrographs of day 25 pancreatic differentiation cultures of transgene-rescued (iPSC1+SBDS) and SBDS-deficient (iPSC1-SBDS) SDS-iPSC-1. Images
are similar for SBDSi hESC.
(E) Photomicrographs of IF staining of transgene-rescued (iPSC1+SBDS) and SBDS-deficient (iPSC1-SBDS) SDS-iPSC-1 for amylase (purple) and DBA (pink) at
day 25 of in vitro pancreatic differentiation. Yellow stars indicate areas of cell death. Gray stars indicate areas with loss of ductal continuity. Images are similar for
SBDSi hESC.
Error bars represent SEM; red bars represent transgene-corrected cells; yellow bars represent SBDS-deficient cells. The number of biological replicates was
between 3 and 6 for all data points. *0.01 < p < 0.05; **p < 0.01. See also Figure S3 and Tables S4 and S5.
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Stem Cell Models of Shwachman-Diamond Syndromestaining and the percentage of cells positive for Annexin V (Fig-
ures 2H and 2I). These data argue that reduction of SBDS protein
levels is associated with reduced survival of terminally differenti-
ated exocrine pancreatic cells.
Ductal Development and Tissue Organization Is
Impaired in SDS Pancreatic Cultures
Gross examination of pancreatic differentiation cultures for
SBDS-deficient cell lines suggested a marked disruption of
cellular architecture. Therefore, we assessed ductal and endo-
crine cell fates among our pancreatic differentiation cultures. In
transgene-rescued cultures, IF staining for Dolichos biflorus
agglutinin (DBA), a ductal marker, revealed that ductal tissue
developed in an organized fashion, creating tube-like structures
between colonies of acinar cells (Figure 3A). In differentiated
cultures of SBDS-deficient hESCs and SDS-iPSC-1, we ob-
served a significant reduction in the percentage of cells staining
positive for DBA (Figure 3B) and in gene expression for CK19, a
duct-specific cytokeratin (Figure 3C), compared to their gene-
rescued counterparts. Again, as seen in differentiated cultures
of exocrine cells, iPSC2-SBDS showed no deficiency in ductal
development, but further depletion of SBDS protein by addition
of SBDS RNAi reduced the percentage of DBA+-staining cells
(Figure 3B).
With regard to endocrine cell fate, we found only trace insulin
positivity as measured by IF staining and limited staining for730 Cell Stem Cell 12, 727–736, June 6, 2013 ª2013 Elsevier Inc.c-peptide (Figure S3A). The presence of SBDS resulted in no sig-
nificant difference in the percentage of cells staining positive for
c-peptide (Figure S3B) or in gene expression for insulin when
measured by qRT-PCR (Figure S3C). These data are consistent
with prior reports showing low levels of endocrine commitment
using comparable protocols (Chen et al., 2009), indicating that
our culture conditions reflect differentiation predominantly to-
ward ductal and exocrine cell fates.
In vitro pancreatic differentiation of normal hESCs and iPSCs
produces acinar-like colonies of exocrine cells separated by
interlobular septa and ductal tissue; these structures resemble
two-dimensional pancreatic lobules. In contrast, differentiated
cultures of SBDS-deficient hESCs and SDS-iPSC-1 displayed
thickening of the interlobular septa, disruption of the ordered
acini-like lobules, and increased regions of cell death (Figures
3D and 3E), as confirmed by expression of Annexin V. Gene
rescue of SBDS restored the appearance of organized pancre-
atic lobules and acini-like structures with reduced patches of
dead cells in both SBDSi hESC and SDS-iPSC-1 differentiation
cultures. Again, SDS-iPSC-2 cultures failed to manifest cell-
death phenotypes, irrespective of gene rescue.
Impaired Hematopoietic Development from SDS
Pluripotent Stem Cells
We used an erythroid body (EB)-based in vitro hematopoietic
differentiation protocol to investigate the effects of SBDS
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Figure 4. SBDS Loss Leads to Reduced
Myeloid Hematopoietic Development
(A) Percentage of SBDSi hESC and SDS-iPSC-2
positive for the leukocyte antigen CD45, deter-
mined by flow cytometry. We included control
hESC and iPSC lines for comparison.
(B) Relative total hematopoietic cfus of SBDSi
hESC and SDS-iPSC-2.
(C) Relative gene expression of representative
hematopoietic markers (TAL1, SPI1, and GATA2),
determined by RT-PCR. We normalized results on
cell lines with gene rescue to 100%.
Error bars represent SEM; red bars represent
transgene-corrected cells; yellow bars represent
SBDS-deficient cells; blue bars represent control
cells. All experiments were performed on day 20
EB-derived cells. The number of biological repli-
cates was between 4 and 5 for all data points.
*0.01 < p < 0.05; **p < 0.01. See also Figure S4 and
Tables S4 and S5.
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Stem Cell Models of Shwachman-Diamond Syndromedeficiency on blood phenotypes. We differentiated all cell lines,
disaggregated EBs at various time points, and analyzed with
qRT-PCR, flow cytometry, and methylcellulose colony-forming
unit (cfu) assays. Time-course studies from day 10 onward iden-
tified days 18–22 as a plateau of maximal hematopoietic activity
in normal cell lines.
At day 20 of in vitro hematopoietic differentiation, hESC and
SDS-iPSC-2 cultures without transgene rescue displayed a
decreased percentage of CD45+ cells as measured by flow
cytometry (Figure 4A), reduced hematopoietic cfus (Figure 4B),
and reduced mRNA expression for hematopoietic transcription
factors (TAL1, SPI1, and GATA2) (Figure 4C). Three hESC and
two iPSC normal control lines displayed CD45 positivity compa-Cell Stem Cell 12, 727–rable to that of SBDS transgene-rescued
hESC and SDS-iPSC-2 (%CD45: 33.2 ±
4.3), indicating that transgene rescue
does not augment hematopoietic poten-
tial above normal levels. Instead,
SBDS deficiency correlates with reduced
hematopoietic differentiation in vitro.
Among the hematopoietic colonies de-
tected in our differentiation cultures, we
observed no significant lineage skewing
as assessed by cfu assay (cfu-granulo-
cyte, cfu-macrophage, cfu-granulocyte/
macrophage), flow cytometry for markers
of erythroid (glycophorin A), neutrophil
(CD15), or monocyte/macrophage line-
ages (CD11b), or gene-expression anal-
ysis of proteins highly expressed in eryth-
rocytes (HGB1), neutrophils (ELANE), and
macrophages (CSF1R) (Figures S4A–
S4C). To exclude a general defect in
mesodermal lineage specification, we
interrogated endothelial (TEK and CDH5)
and cardiac (NKX2-5 and myocardin)
markers by qRT-PCR and found no
significant differences irrespective oftransgene rescue (Figure S4D). Moreover, analysis of SBDSi
hESC- and SDS-iPSC-2-derived teratomas showed no general-
ized loss of mesodermal structures.
Surprisingly, SDS-iPSC-1 displayed minimal hematopoietic
activity upon differentiation, regardless of transgene rescue,
generating less than 1% CD45+ hematopoietic cells at day 20
of hematopoietic differentiation and never developing hemato-
poietic cfus in six separate experiments. The diminished
hematopoietic activity of SDS-iPSC-1 may reflect the known
clonal variation in the differentiation potential of human pluripo-
tent stem cells (Osafune et al., 2008). Given the absence of
SBDS-dependent hematopoietic phenotypes in SDS-iPSC-1,
we excluded these cells from subsequent analyses.736, June 6, 2013 ª2013 Elsevier Inc. 731
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Figure 5. Elevated Protease Activity Links Pancreatic and Hematopoietic Phenotypes
(A) Photomicrographs of SDS-iPSC-1 day 25 pancreatic differentiation cultures stained with H&E and pancreatic autopsy samples at 50X and 100 X magnifi-
cations. The slides from a deidentified patient were obtained from the collection of Dr. H. Shwachman (Boston Children’s Hospital) and processed in 1967. Please
excuse black streaking artifacts from aging.
(B) Electron micrograph demonstrating granule number and structure in day 25 pancreatic differentiation cultures. The size marker represents 1 mm.
(C) Photomicrogaph of SBDSi hESC day 20 EB-derived hematopoietic cells stained with Wright-Giemsa. SBDS-deficient hESC (hESC-SBDS) monocytes show
increased prominence of azurophilic granules (red-purple) with a comparable number of eosinophilic (red-orange) secondary granules. SBDS-deficient hESC
myeloid precursors show a similar increase in azurophilic granules.
(D) Relative protease activity as determined by protease-activity assay in SDS-iPSC-1 day 25 pancreatic supernatants and SBDSi hESC day 20 EB-derived liquid
hematopoietic cultures.
(E) Percentage of cell viability as determined by trypan-blue exclusion of SDS-iPSC-1 day 25 pancreatic cultures. Aprotinin treatment (1 mM) occurred every
2 days beginning at day 13 in SBDS-deficient cells (iPSC1-SBDS).
(F) Photomicrographs from SDS-iPSC-1 day 25 pancreatic cultures. Black and brown patches represent areas of increased cell death.
(G) Change in exocrine cell number from day 25 to day 35 in SDS-iPSC-1 pancreatic cultures. We normalized results for transgene-corrected cells to 1.
(H) Percentage of cell viability as determined by trypan-blue exclusion after 12 hr exposure to IMDM+1%serum in SBDSi hESCday 20 EB-derived hematopoietic
cells. Protease inhibitor cocktail was diluted at 1:400.
Error bars represent SEM; red bars represent transgene-corrected cells; yellow bars represent SBDS-deficient cells. *0.01 < p < 0.05. See also Tables S1– S3
and S5.
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Stem Cell Models of Shwachman-Diamond SyndromeElevated Protease Activity Links Pancreatic and
Hematopoietic Phenotypes in SDS
The exocrine pancreas and cells of themyeloid lineage, including
neutrophils, are characterized by large numbers of cytotoxic
granules. Production of proteases in the proenzyme form in
exocrine pancreas, and appropriate targeting and packaging
of proteases in myeloid cells protect against autodigestion.732 Cell Stem Cell 12, 727–736, June 6, 2013 ª2013 Elsevier Inc.Routine microscopic analysis of exocrine cells in day 25 pancre-
atic differentiation cultures demonstrated different granule mor-
phologies between SBDS-deficient and transgene-rescued
cells. Histologic staining and electron microscopy of SBDS-defi-
cient SDS-iPSC-1 cultures confirmed both increased granule
size and number per cell compared to transgene-rescued coun-
terparts (Figures 5A and 5B; Table S1). The SBDS-deficient iPSC
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Stem Cell Models of Shwachman-Diamond Syndromecultures possessed cellular phenotypes similar to those ob-
served in patient samples (Figure 5A). These differences may
reflect immaturity of the granules, given that zymogen granules
lose volume during maturation through tighter aggregation
of secretory proteins, or they may reflect a failure of other
regulated steps in the granule-trafficking pathway. Similarly, his-
tological analysis of day 20 EB-derived hematopoietic cells
differentiated fromSBDS-deficient hESCs revealed an increased
staining of primary azurophilic granules within promyelocytes
and monocytes compared to transgene-rescued SBDSi hESCs
(Figure 5C).
Proteases are a major component of both pancreatic
zymogen and myeloid azurophilic granules. We reasoned that
the presence of such granules might correlate with aberrant
enzymatic activation and that release of granule enzymes
leading to autodigestion might contribute to SDS pathology.
We subjected media from day 25 pancreatic and day 20
hematopoietic cultures (containing mostly neutrophil progeni-
tors and monocytes/macrophages) to a protease-activity
assay. We studied SBDS-deficient SDS-iPSC-1 for pancreatic
differentiation and SBDS-deficient hESCs for hematopoietic
differentiation, because these lines displayed the most dra-
matic phenotypes. Both these pancreatic and hematopoietic
cultures displayed significantly elevated levels of protease
activity compared to transgene-rescued lines (Figure 5D). At
baseline, SBDS-deficient SDS-iPSC-1 day 25 pancreatic cul-
tures show significantly increased cell death compared to its
transgene-rescued counterpart (Figures 5E and 5F). To test
whether the elevated protease levels had functional conse-
quences that account for cell death, we administered a phar-
macological blockade of potentially cytotoxic enzymes within
granules. We treated SBDS-deficient SDS-iPSC-1 pancreatic
cultures with the serine protease inhibitor aprotinin, a broad-
spectrum protease inhibitor cocktail, a lipase inhibitor, and
a pan-caspase inhibitor. Treatment occurred from day 13
onward, coincident with the formation of mature pancreatic
cell types with prominent granules. Aprotinin treatment signifi-
cantly reduced cell death (Figures 5G) and also normalized
colony morphology, reducing thickening of the interlobular
septa in two-dimensional culture and reducing regions of cell
death (Figure 5F). Treatment with the protease inhibitor cocktail
initially demonstrated improvements similar to those of aproti-
nin alone, but it was toxic to cells and eventually led to
increased cell death (Table S2).
We performed parallel experiments targeting primary azuro-
philic granules in hematopoietic cultures. Irrespective of gene
rescue, day 20 EB-derived cells fromSBDS-deficient hESCs dis-
played robust proliferation with minimal cell death (<2%) in liquid
cultures with 20% serum and hematopoietic cytokines. How-
ever, stressing cells with a 12 hr exposure to low-serum (1%)
conditions exposed significantly higher rates of cell death in
SBDS-deficient hESC hematopoietic cells compared to the
transgene-rescued cell line (Figure 5H), suggesting stress-
induced apoptosis may contribute to the hematopoietic pheno-
type. In low-serum conditions, we treated SBDS-deficient hESC
hematopoietic cells with inhibitors including aprotinin, the broad-
spectrum protease inhibitor cocktail, neutrophil elastase inhibi-
tor sivelestat, a myeloperoxidase inhibitor, and a pan-caspase
inhibitor. The pan-caspase inhibitor dramatically increased cellsurvival to levels above the transgene-corrected SBDSi hESC
hematopoietic cultures (Table S3), which probably reflects
inhibition of baselines levels of apoptotic cell death in normal
cultures. Among the granule enzyme inhibitors, only the broad-
spectrum protease inhibitor cocktail significantly reversed the
increased cell death in SBDS-deficient hESC hematopoietic
cultures (Table S3), which may reflect the importance of nonser-
ine proteases such as cathepsin B and cathepsin D in myeloid
granules or the synergistic effect of blocking a number of
protease types.
DISCUSSION
SDS is a rare, autosomal-recessive disorder characterized by
developmental dysfunction of the exocrine pancreas, bone
marrow failure, and predisposition to infection and leukemia. In
this study, we present a human model of SDS based on pluripo-
tent stem cells. Using lentiviral SBDS RNAi in hESCs and direct
reprogramming of SDS patient fibroblasts, we generated hESCs
and iPSCs that meet the widely accepted standards of pluripo-
tency (Maherali and Hochedlinger, 2008) but also manifest
dysfunction of ribosomal assembly, a biochemical feature of
the class of bonemarrow disorders characterized by ribosomop-
athy. Upon in vitro pancreatic differentiation, SBDS-deficient
hESCs and iPSCs displayed an SBDS-dependent, progressive
loss of exocrine tissue with increased cell death and impaired
architecture of the self-organizing acinar-like structures that
develop in culture. Hematopoietic development was also
compromised in our hESCs and iPSCs. SDS hESCs and iPSCs
displayed a reduced percentage of CD45+ cells, a decreased
level of cfu production, and a gene-expression profile reflecting
impaired myeloid development without general loss of meso-
dermal potential. We did not observe lineage skewing or matura-
tion defects upon prolonged culture; however, EB-derived
hematopoietic cells (mostly neutrophil progenitors and mono-
cytes) had significantly increased levels of cell death in
low-serum conditions, suggesting that cellular-stress-induced
apoptosis contributes to neutropenia (Yamaguchi et al., 2007).
Our human pluripotent stem cell system enables a scalable
model of human material for investigating SDS.
Our results suggest amechanistic link between exocrine insuf-
ficiency and hematopoietic dysfunction in SDS. Granule size and
number were increased in SBDS-deficient SDS-iPSC-1 pancre-
atic cultures relative to transgene-corrected cells, and likewise,
the azurophilic primary granules of promyelocytes, myelocytes,
and monocytes were more prominent in SBDS-deficient EB-
derived hematopoietic cultures. These granular changes parallel
the significantly higher protease-activity levels we detected in
both cell types. Proteases such as trypsin should not normally
be active because they are stored and secreted as inactive pro-
enzymes such as trypsinogen. However, our data correlate high
protease levels with autodigestion and cell death in vitro, sug-
gesting that autodigestion as a result of granule abnormalities
constitutes a pathological link between the pancreatic and
hematopoietic dysfunction observed in SDS. Other tissues with
high digestive-granule content have also been shown to be
defective in patients with SDS, including osteoclasts (Toiviai-
nen-Salo et al., 2007), intestinal cells (Shah et al., 2010), and
parotid glands (Stormon et al., 2010), suggesting a commonCell Stem Cell 12, 727–736, June 6, 2013 ª2013 Elsevier Inc. 733
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affected tissues, presumably due to vacuolar processing
defects.
In ourmodel, pharmacological inhibition of proteases reversed
the aberrant cellular phenotypes in vitro. Aprotinin was
previously approved by the US Food and Drug Administration
(Trasylol; Bayer) and marketed for the reduction of transfusion
requirements in patients undergoing cardiac bypass surgery,
but its use was discontinued because of safety concerns. It is
tempting to speculate that drug treatment might reduce or pre-
vent acinar cell death or ameliorate neutropenia in SDS patients
if it can be tolerated. In addition to inhibiting trypsin directly,
aprotinin can inhibit autophagy (Chau et al., 2003). In hematopoi-
etic cell cultures, we also observed a reduction in cell death after
treatment with an antiproteolytic cocktail, suggesting additional
benefit in exploring a wider range of antiproteolytics, given that
blocking nonserine proteases, such as cathepsin B, may elimi-
nate direct and synergistic protease effects of an autodigestive
process.
Our study highlights both the advantages and the limitations of
pluripotent stem cell-based models of human pathology. In both
pancreatic and hematopoietic differentiation assays, variability
existed in the different isolates of SBDS-deficient hESCs and
iPSCs. Most notably, SDS-iPSC-2 displayed a discernible
hematopoietic, but not an exocrine pancreatic, phenotype.
SDS-iPSC-2 retained the largest residual SBDS expression
(30% of normal, whereas SBDSi hESC expressed 7%, and
SDS-iPSC-1 <1%). Phenotypic variability may reflect residual
SBDS function, as suggested in previous patient-based obser-
vations (Minelli et al., 2009). To confirm a relationship between
phenotype and SBDS expression, we depleted SBDS protein
further via RNAi knockdown in SDS-iPSC-2 cells and observed
decreased pancreatic exocrine function, consistent with the
correlation between phenotype and protein levels. However,
genetic background may also account for phenotypic variation.
A range of 11%–29% of SDS patients lack any known SBDS
genetic variant (Boocock et al., 2003; Nakashima et al., 2004;
Woloszynek et al., 2004); these patients exhibit severe hemato-
poietic diseasewith verymild pancreatic manifestations (Hashmi
et al., 2011), supporting genotype-phenotype relationships.
Complex genetic backgrounds probably explain the combina-
tion of manifestations, pancreatic or hematologic, observed in
SDS patients and may distinguish related syndromes such as
SDS, Johanson-Blizzard syndrome, Pearson marrow-pancreas
syndrome, dyskeratosis congenita, and Fanconi anemia. Impor-
tantly, however, there is considerable variability in the differenti-
ation propensities of distinct pluripotent stem cell clones
(Osafune et al., 2008), but the underlying mechanisms of this
heterogeneity remain unclear. Therefore, assessment of pheno-
typic reversion for transgene-corrected clones is imperative for
concluding a link between genotype and phenotype in pluripo-
tent stem cell models of disease.
hESCs and iPSCs provide an in vitro model of target organ
tissues for discerning the relationship between complex genetic
backgrounds and cellular phenotypes. For example, we con-
firmed the presence of the 258+2T>C (rs113993993) and
621+1G>A mutations in SDS-iPSC-2. The 258+2T>C mutation
has been detected in patients with acquired aplastic anemia
with early presentation, poor outcomes, and absence of the734 Cell Stem Cell 12, 727–736, June 6, 2013 ª2013 Elsevier Inc.pancreatic manifestations characteristic of SDS (n = 4) (Calado
et al., 2007). The mutation 621+1G>A, a rare variant, has been
observed in a patient with inherited bone marrow failure who
developed severe neutropenia, but no pancreatic insufficiency
(Tsangaris et al., 2011). SDS-iPSC-2 pancreatic culture, which
carries these two mutations, did not exhibit the expected
decrease in pancreatic exocrine cell numbers compared to its
transgene-rescued counterpart, consistent with the lack of
pancreatic manifestations described above. Although this
patient met clinical criteria for SDS, his pancreatic involvement
was limited to low-level serum trypsinogen. Therefore, the
clinical presentation of the iPSC donor is reflected in our model.
Perhaps 183-184TA>CT (rs120074160), which can be found
in most patients including the source of SDS-iPSC-1, but
not SDS-iPSC-2, contributes to the pancreatic phenotype by
lowering SBDS protein levels below the threshold necessary
for healthy pancreatic function. Additional analyses with iPSC
lines from patients with known clinical histories and genotypes
may associate genetic variants with functions to personalize
diagnosis and therapeutic decisions.
Our observation of increased granule size and number in
exocrine pancreatic cells derived in vitro from patients with
SDS contrasts with the cellular phenotype of a recently
described murine model that manifests pancreatic features
similar to those of human SDS. These mice were derived from
a Sbds conditional knockout allele and/or a point mutation
generated by site-directed mutagenesis (Tourlakis et al., 2012).
In these mice, microscopy revealed normal structure but a
marked reduction in the number of acinar zymogen granules,
whereas our human model showed an increase in granule
number and size for both acinar zymogen granules and azuro-
philic granules in hematopoietic cells. These varied results could
reflect an inherent difference between human and mouse
disease models or between in vitro and in vivo systems; it could
also reflect an unrelated variable, such as granule maturation,
time between feeding and tissue procurement (given that
feeding influences zymogen granule number), or lack of an un-
known systemic factor.
Our work establishes a new human cell-based model sys-
tem for SDS that demonstrates distinctive developmental
phenotypes not easily studied in other contexts. Future
studies of inherited bone-marrow-failure syndromes can benefit
from hESC and iPSC models that reveal genotype-phenotype
relationships. Furthermore, our finding of elevated protease
levels and rescue by pharmacological blockade in vitro in
both pancreatic and hematopoietic lineages suggests a com-
mon functional pathway and potential therapeutic strategies
in SDS.EXPERIMENTAL PROCEDURES
hESC and iPSC Cell Culture Production and Maintenance
We maintained hESCs and iPSCs as undifferentiated cells on inactivated pri-
mary mouse embryonic fibroblasts (MEFs) (Millipore). We reported derivation
of iPSCs from patients with SDS previously (Park et al., 2008).
For small interfering RNA vector, we cloned three oligonucleotides encoding
stem-loop structures targeting SBDS under the control of the human U6
promoter in the pLentilox vector (Rubinson et al., 2003). The targeting
sequences within SBDS are AACATGCTGCCATAACTTAGATT, AAGCTTG
GATGATGTTCCTGATT, and AAGGAAGATCTCATCAGTGCGTT.
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infected hESCs via FACS and manual selection of GFP-positive colonies.
We infected SBDSi hESC lines with a mixture of three knockdown viruses
with different target sequences.
We cloned human SBDS cDNA into pSin-EF2-Nanog-Puro (Addgene),
replacing the NANOG cDNA. We then transduced hESCs and iPSCs on
Matrigel (BD Biosciences) in MEF-conditioned media with single-round infec-
tions for 24 hr, followed by expansion ontoMEFs and two rounds of puromycin
selection (1 mg/ml) for 72 hr.We verified gene correction via western blotting for
SBDS (Abcam).
We injected NOD/SCID mice subcutaneously with 1–2 3 106 hESCs or
iPSCs. We excised teratomas and analyzed them histologically in a blinded
fashion for tissues from all three embryonic germ layers. We fixed pancreatic
differentiation cultures for 20 min in 4% paraformaldehyde (PFA, Sigma-
Aldrich) and stained with hematoxylin and eosin (H&E). We stained cytospins
of EB-derived hematopoietic cells and liquid cultures with Wright-Giemsa.
We used a Nikon Eclipse E400 microscope at 100X magnification and ImageJ
software (http://rsbweb.nih.gov/ij/index.html).
Ribosomal Profiling
We extracted iPSCs in polysome buffer, loaded extracts onto 5%–50%
sucrose-density gradients (20 mM HEPES [pH 7.4], 100 mM KCl, 10 mM
MgCl2, 100 mg/ml cycloheximide, 200 mg/ml heparin), and centrifuged
for 2 hr at 4C in an SW41 rotor. We collected gradient fractions with a
Teledyne Isco UA-6 with continuous UV monitoring at 254 nm. We quantitated
areas under the curve for the 40S and 60S subunits and 80S ribosomal peaks
using digitally captured A254nm absorbance readings (Burwick et al., 2012).
Because we cultured SDS-iPSC-1 over an MEF layer, we harvested MEFs
without iPSCs for polysome profiling and detected minimal background
signals.
Pancreatic Differentiation and Immunostaining
We cultured hESCs and iPSCs on MEF layers until 50% confluent, generally
1–2 days after splitting, and differentiated as described previously (Chen
et al., 2009) and repeated in detail in the Supplemental Information. For endo-
crine development, we used a published protocol (Nostro et al., 2011).
For immunostaining, we fixed cells in 4% PFA for 20 min at room tempera-
ture and immunostained using the following primary antibodies: anti-FOXA2
(Millipore, 07-633; 1:500), anti-SOX17 (R&D Systems, AF1924; 1:500), anti-
PDX1 (R&D Systems, AF2419; 1:500), anti-amylase (Novus Biologicals,
NBP1-21420; 1:200), anti-DBA (Vector Labs, B-1035; 1:400), and anti-insulin
(Abcam, ab7842; 1:100). We used Alexa-488-, Alexa-555-, and Alexa-647-
conjugated secondary antibodies at 1:500 (Life Technologies) and obtained
images on a BD Pathway using a 7 3 7 montage automatic capture to allow
for unbiased acquisition. We scored images using ImageJ software and
confirmed counts of test regions manually.
Hematopoietic Differentiation of hESCs and iPSCs and Analysis
We obtained single-cell suspensions from EB-differentiated hESCs and iPSCs
as described previously (Chadwick et al., 2003). We stained for the markers
CD45, CD15, CD11b (R&D Systems), and glycophorin A (BD Biosciences)
for 30 min on ice, followed by two washes with PBS, and analyzed using a
FACSCalibur (BD Biosciences). We plated EB-differentiated hESC and
iPSC populations (1 3 104–2 3 105) into methylcellulose H4434 (Stem Cell
Technologies) and incubated them at 37C and 5% CO2 for 14 days.
Gene-Expression Analysis
We obtained multiple independent biological samples for RNA isolations and
extracted total RNA using the RNeasy Plus kit (QIAGEN). We prepared
cDNA using the SuperScript VILO cDNA Synthesis Kit (Life Technologies)
according to manufacturer’s instructions. We performed RT-PCR with SYBR
green reagent kits (Agilent Technologies) on a Stratagene Mx3005P quantita-
tive PCR machine using primers from Integrated DNA Technologies. Primer
sequences are listed in Table S4.
Protease Assay
We used the EnzCheck Protease Assay Kit (Life Technologies) to measure
protease activity from supernatants of day 25 pancreatic and day 20 EBhematopoietic cultures. In brief, this kit involves incubating samples for 1 hr
with intramolecularly quenched substrate (BODIPY FL casein) and detecting
fluorescently cleaved products on a microplate reader. The EnzCheck
Protease Assay is broadly sensitive, with the capacity to detect serine, acid,
sulfhydryl, and metalloproteases. We selected controls of media from
undifferentiated hESCs and standardized against titrations of trypsin activity.
Pharmacological Inhibition of Granule Enzymes and Cell-Death
Analysis
We treated pancreatic differentiation cultures with the following inhibitors
every 2 days beginning on day 13 of differentiation: aprotinin (Sigma-Aldrich,
A6103), protease inhibitor cocktail (Sigma-Aldrich, P1860), pan-caspase
fmk inhibitor Z-VAD (R&D Systems, FMK001), and orlistat (Sigma-Aldrich,
O4139). We resuspended day 20 EB-derived hematopoietic cells in Iscove’s
modified Dulbecco’s media (IMDM) + 1% FBS and placed it on a shaker for
12 hr with the following inhibitors: aprotinin, protease inhibitor cocktail, pan-
caspase fmk inhibitor, sivelestat (Sigma-Aldrich, S7198-5MG), and myeloper-
oxidase inhibitor-I (Santa Cruz Biotechnologies, sc-204107). We calculated
cell viability via trypan blue exclusion and performed annexin V and propidium
iodide analyses of pancreatic cultures using the Alexa Fluor 488 Annexin
V/Dead Cell Apoptosis Kit (Life Technologies).
Statistical Analysis
We used Student’s t test for pairwise statistical analysis. p values are pre-
sented in Table S5.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, five tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.stem.2013.04.002.
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